Paradromics
Austin-based brain-computer-interface company developing the Connexus implant to restore communication for paralyzed patients; grew its core neural-recording technology under a competitively-won $18.3M DARPA Neural Engineering System Design contract explicitly tied to an injured-veterans neural-prosthetics program.
Paradromics is an Austin, Texas brain-computer-interface (BCI) company founded in 2015 by CEO Matt Angle to commercialize high-data-rate neural-recording technology developed at Stanford into a fully-implantable, wireless device. Its flagship Connexus Direct Data Interface targets patients with severe paralysis from ALS, spinal cord injury, or stroke, restoring communication by decoding signals from the brain's speech-related cortex; Connexus received FDA Breakthrough Device designation, and in November 2025 the FDA approved Paradromics' "Connect-One" early feasibility clinical study, the first IDE approval granted for speech restoration with a fully implantable BCI. DARPA funded Paradromics' early R&D: in July 2017 it selected Paradromics — the only startup among six winners, the rest universities — for an $18.3M Neural Engineering System Design (NESD) contract to build a high-bandwidth neural interface, then added $8M in 2019 under a DARPA program for injured veterans. The company has since raised a $20M seed round (2021, led by Alpha Edison) and a $33M Series A (2023, led by Prime Movers Lab, with Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity), plus additional Series A and grant funding (including an HHS grant) into 2025, for cumulative funding of roughly $88.7M.
Overview
- Headquarters
- Austin, TX
- Founded
- 2015
- Employees
- Total funding
- Stage
- Status
- active
- Domains
- Website
- www.paradromics.com
Founders2
- FounderMatt AngleFounder and CEO of Paradromics; neuroscientist trained at Heidelberg University and Stanford who translated high-data-rate neural-recording research into a commercial brain-computer-interface company.
- FounderAdam KablanianSilicon Valley semiconductor entrepreneur and angel investor; co-founder of Virage Logic, PlasmaSi, and Memoir Systems; CEO of cynora GmbH; founding board chairman and lead investor of neural-interface startup Paradromics; controlling manager of the SPV fund:matadero-qed.
Investors0
No linked records yet.
Cap table0
Approximate ownership by holder. Indexed holders link to their records.
| Holder | Instrument | Ownership |
|---|
Contracts0
No linked records yet.
Programs0
No linked records yet.
Frequently asked
- What does Paradromics do?
- Paradromics is an Austin, Texas brain-computer-interface (BCI) company founded in 2015 by CEO Matt Angle to commercialize high-data-rate neural-recording technology developed at Stanford into a fully-implantable, wireless device. Its flagship Connexus Direct Data Interface targets patients with severe paralysis from ALS, spinal cord injury, or stroke, restoring communication by decoding signals from the brain's speech-related cortex; Connexus received FDA Breakthrough Device designation, and in November 2025 the FDA approved Paradromics' "Connect-One" early feasibility clinical study, the first IDE approval granted for speech restoration with a fully implantable BCI. DARPA funded Paradromics' early R&D: in July 2017 it selected Paradromics — the only startup among six winners, the rest universities — for an $18.3M Neural Engineering System Design (NESD) contract to build a high-bandwidth neural interface, then added $8M in 2019 under a DARPA program for injured veterans. The company has since raised a $20M seed round (2021, led by Alpha Edison) and a $33M Series A (2023, led by Prime Movers Lab, with Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity), plus additional Series A and grant funding (including an HHS grant) into 2025, for cumulative funding of roughly $88.7M.
- Where is Paradromics headquartered?
- Paradromics is headquartered in Austin, TX and was founded in 2015.
Sources & citations4
Each claim links to its underlying source. Confidence reflects how directly the source supports the claim.
- 1
DARPA selected Paradromics — the only startup among six winners, the rest universities — for a competitively-procured $18.3M Neural Engineering System Design (NESD) contract in July 2017 to build a high-bandwidth neural interface
Forbes: DARPA Invests $18.3 Million In Brain Implant Startup That's Building 'A Modem For The Mind'Verified2017-07-10 - 2
Paradromics received FDA approval for its Connect-One early feasibility clinical study with the Connexus brain-computer interface, the first IDE approval for speech restoration with a fully implantable BCI
Business Wire: Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus Brain-Computer InterfaceVerified2025-11-20 - 3
Paradromics raised a $33M Series A round led by Prime Movers Lab, with Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity participating, to fund its first-in-human Connexus clinical trial
PR Newswire: Paradromics Raises $33 Million in Funding, Achieves Breakthrough Medical Device Designation from FDAVerified2023-01-01 - 4
DARPA's neural-implant program for injured veterans awarded Paradromics an additional $8M in 2019
ClearanceJobs: DARPA's Neural Implant Program for Injured Vets Awards Paradromics Inc. Additional $8MVerified2019-07-12